Tag Archives: Mayank Mamtani

NGM Biopharmaceuticals Inc (NGM) Gets a Buy Rating from B.Riley FBR

NGM Biopharmaceuticals Inc (NGM – Research Report) received a Buy rating and a $24.00 price target from B.Riley FBR analyst Mayank Mamtani today. The company’s shares closed last Monday at $10.28, close to its 52-week low of $8.81. According to

Arbutus Biopharma Corporation (ABUS) Receives a Buy from B.Riley FBR

B.Riley FBR analyst Mayank Mamtani maintained a Buy rating on Arbutus Biopharma Corporation (ABUS – Research Report) today and set a price target of $3.00. The company’s shares closed last Monday at $1.02, close to its 52-week low of $1.00.

Analysts Offer Insights on Healthcare Companies: Medicines Co (NASDAQ: MDCO) and ChemoCentryx (NASDAQ: CCXI)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Medicines Co (MDCO – Research Report) and ChemoCentryx (CCXI – Research Report) with bullish sentiments. Medicines Co (MDCO) B.Riley FBR analyst Mayank

B.Riley FBR Reaffirms Their Buy Rating on Genfit SA (GNFT)

In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Genfit SA (GNFT – Research Report), with a price target of $52. The company’s shares closed last Monday at $16.67, close to its 52-week low

B.Riley FBR Reaffirms Their Buy Rating on Medicines Co (MDCO)

In a report released today, Mayank Mamtani from B.Riley FBR maintained a Buy rating on Medicines Co (MDCO – Research Report), with a price target of $61. The company’s shares closed last Monday at $35.03. Mamtani said: “Company (MDCO) issued

Dicerna Pharma (DRNA) Gets a Buy Rating from B.Riley FBR

In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Dicerna Pharma (DRNA – Research Report), with a price target of $24. The company’s shares closed on Friday at $13.59. Mamtani noted: “Pharmaceuticals (DRNA) reported